达格列净对2型糖尿病合并阵发性房颤患者心功能及炎症因子的影响分析

Effect of dapagliflozin on cardiac function and inflammatory factors of patients with type 2 diabetic mellitus with paroxysmal atrial fibrillation

目的探讨达格列净对2型糖尿病(type 2 diabetes mellitus,T2DM)合并阵发性房颤(paroxysmal atrial fibrillation,PAF)患者心功能及血清炎症因子的影响。方法选取2021年1月至2022年6月蚌埠市第一人民医院收治的T2DM合并PAF患者100例,根据治疗方案将其分为对照组和观察组,每组各50例。两组患者均给予常规治疗,观察组患者在此基础上予以达格列净治疗,两组患者均治疗6个月。比较两组患者治疗前后心功能指标及血清炎症因子水平。结果治疗6个月后,两组患者的左室舒张末期内径(left ventricular end diastolic diameter,LVEDD)、左心房内径(left atrium diameter,LAD)均显著小于本组治疗前,左室射血分数(left ventricular ejection fraction,LVEF)均显著高于本组治疗前,血清超敏C反应蛋白(hypersensitive C-reaction protein,hsCRP)、白细胞介素-6(interleukin-6,IL-6)、单核细胞/高密度脂蛋白胆固醇比值(monocyte to high density lipoprotein-cholesterol ratio,MHR)均显著低于本组治疗前(P<0.05);观察组患者的LVEDD、LAD均显著小于对照组,LVEF显著高于对照组,血清hsCRP、IL-6、MHR均显著低于对照组(P<0.05)。结论达格列净可显著改善T2DM合并PAF患者的心功能,降低炎症因子水平,具有较好的临床应用价值。

Objective To investigate the effect of dapagliflozin on cardiac function and inflammatory factors of patients with type 2 diabetic mellitus(T2DM)with paroxysmal atrial fibrillation(PAF).Methods A total of 100 T2DM patients with PAF treated in Bengbu First People’s Hospital from January 2021 to June 2022 were selected and divided into control group and observation group according to the treatment plan,with 50 cases in each group.Patients in both groups were given conventional treatment,and patients in observation group were given dapagliflozin on the basis of conventional treatment.Both groups were treated for 6 months.The cardiac function indexes and serum inflammatory factors were compared between two groups before and after treatment.Results After 6 months of treatment,left ventricular end diastolic diameter(LVEDD)and left atrium diameter(LAD)in both groups were significantly lower than before treatment,left ventricular ejection fraction(LVEF)was significantly higher than that before treatment,and serum hypersensitive C-reaction protein(hsCRP),interleukin-6(IL-6)and monocyte to high density lipoprotein-cholesterol ratio(MHR)were significantly lower than before treatment(P<0.05).LVEDD and LAD in observation group were significantly lower than those in control group,LVEF was significantly higher than those in control group,serum hsCRP,IL-6 and MHR were significantly lower than those in control group(P<0.05).Conclusion Dapagliflozin can significantly improve the cardiac function and reduce the level of inflammatory factors in T2DM patients with PAF,which has good clinical application value.